Nrg-Hn004- Randomized Phase II/III Trial Of Radiotherapy With Concurrent Medi4736 (Durvalumab) Vs. Radiotherapy With Concurrent Cetuximab In Patients With Stage III-Ivb Head And Neck Cancer With A Contraindication To Cisplatin
Posted Date: May 15, 2019
- Investigator: Vinita Takiar
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
To determine the safety and effectiveness of radiotherapy (RT) with concurrent and adjuvant anti-PD-L1 therapy [MEDI4736 (durvalumab)] is safe in patients with locoregionally advanced head and neck cancer (HNC) who have a contraindication to cisplatin.
Criteria:
To Be Eligible: Must Have Diagnosed Advanced Hnscc With Contraindiction To Cisplatin, Must Be 18 Years Or Older, Bodyweight >30Kg, No Prior Malignancy In <3 Years
Keywords:
Head And Neck Cancer, Phase Ii/Iii
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com